CytoSorbents (CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb cytokine adsorber to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that it has signed an exclusive distribution agreement with Armaghan Salamat Kish Group (Arsak) to distribute CytoSorb for all critical care, cardiac surgery, and other hospital applications in Iran.
Mr. Mohammadreza Hosseini, Chief Executive Officer of Armaghan Salamat Kish stated, "This is a historic moment. In the past, we have seen many hospitalized patients fall victim to sepsis, the systemic inflammatory response syndrome (SIRS), and other related critical conditions.
At those times, we had wished somebody, someday could do something for them and end this nightmare of the critical care world. Now, we are proud to have this agreement with CytoSorbents to help these patients ourselves."
Mr. Hosseini continued, "In our pre-marketing studies, CytoSorb® therapy has generated a lot of attention and interest from key opinion leaders as a new way to control and manage SIRS, treat bacterial infection and toxemia, and prevent multiple organ failure in life-threatening illnesses and complications of cardiac and transplant surgery.
“As the CEO of one of the leading medical device distributors in Iran, we are fully-committed to the commercial and humanitarian success of CytoSorb® in the country, particularly for patients and their families. As our two companies embrace this opportunity, we are reminded of the words of Jacob Bronowski who said, 'Science is the acceptance of what works and what does not. That needs more courage than we might think.'"
Dr. Phillip Chan, CEO of CytoSorbents stated "We are pleased that Armaghan Salamat Kish will be working with us to bring CytoSorb® to hospitalized patients throughout the country.
“Their extensive experience and established dedicated sales force in our common markets make them an ideal partner and will ensure strong synergy. In addition, we share a common dedication to help those patients in greatest need, wherever they may be."
CytoSorb is now distributed in 39 countries throughout the world. Iran has a population of 78 million people, with approximately 550 government funded hospitals that provide inpatient medical care. Health insurance is provided through either private insurance or the Social Security Organization.
Armaghan Salamat Kish Group (Arsak), a biomedical engineering company, was founded in 2005 with highly skilled and experienced engineers and experts.
The company focuses on the importation of high impact medical devices in the areas of Anesthesia, Otolaryngology (ENT), Cardiac surgery, Ophthalmology, and Intensive Care and Regenerative medicine.
Having developed professional relationships with important clinical centers throughout the country, as well as scientific and technical interactions with remarkable doctors and specialists, Armaghan Salamat Kish Co. has maintained considerable collaborations and business partnerships with leading European and American medical device companies.